Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas

Department of Pathology, The Gade Institute, Bergen, Norway.
Apmis (Impact Factor: 1.92). 12/2003; 111(11):1011-8. DOI: 10.1111/j.1600-0463.2003.apm1111103.x
Source: PubMed

ABSTRACT Angiogenesis is a key process in tumour growth and metastasis, and Factor-VIII microvascular density has been found to influence prognosis among endometrial carcinoma patients. The CD105/endoglin antibody has been reported to preferentially bind to activated endothelial cells in tissues participating in angiogenesis, and we therefore wanted to compare the prognostic significance of CD105/endoglin to that of Factor-VIII. In a population-based endometrial carcinoma study with long (median 11.5 years) and complete patient follow-up, mean intratumour microvascular density (MVD) assessed using CD105/endoglin was investigated and compared with previous data for MVD assessed using Factor-VIII. MVD by CD105/endoglin was significantly correlated with MVD by Factor-VIII (p=0.001). However, tumours within the two groups defined by the upper and lower quartiles for CD105/endoglin-MVD were both significantly more often metastatic (FIGO-stage III/IV; p=0.03), with high tumour cell proliferation by Ki67 (p=0.007) and with reduced survival (p=0.036) as compared with the intermediate groups. In Cox regression analysis, CD105/endoglin-MVD showed independent prognostic influence when analysed together with patient age, FIGO stage, histologic subtype, histologic grade and Factor-VIII-MVD, while the latter lost its prognostic impact when CD105/endoglin was included. In the subgroup with high MVD, there was a tendency towards improved response to radiation therapy. In conclusion, CD105/endoglin-MVD is significantly associated with FIGO stage, tumour proliferation and prognosis in endometrial carcinoma, indicating that this is a better angiogenic marker in these tumours.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Alterations of the p53 gene have been widely suggested to be relevant to the development of endometrial carcinoma. However, contradictory results have been reported when immunohistochemical determination of p53 expression has been correlated with stage and histological features of the tumours. Pathology findings were reviewed and p53 immunoperoxidase staining was performed in 240 cases of endometrial carcinoma. Uterine papillary serous adenocarcinomas showed significantly higher p53 overexpression than uterine endometrioid adenocarcinomas (100.0% versus 61.0%, p<0.005). p53 overexpression was significantly higher in the secretory variant (85.7%) than in the typical endometrioid carcinoma (60.0%) (p<0.05). p53 expression did not differ between early (stage I) and advanced (stage II-IV) carcinomas. Likewise, no difference was observed in p53 expression among different architectural grades. The incidence of metastasis to lymph nodes was similar in p53 positive (13.7%) and in p53 negative tumours (12.5%). In the present series, p53 immunostaining did not differ between cases with different FIGO stages or histologic characteristics of the tumours. No simple relationship exists between the immunohistochemical determination of p53 expression and the biological aggressiveness of endometrial carcinomas.
    European Journal of Obstetrics & Gynecology and Reproductive Biology 11/2005; 123(1):111-6. DOI:10.1016/j.ejogrb.2005.03.018 · 1.63 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Wilms tumor (WT), the most common malignant neoplasm of the kidney in infants and children, is a triphasic tumor that mimics various stages of nephrogenesis, composed of epithelial, blastemal and stromal cells. More than 90% of the cases occur in children less than 6-years of age, mostly between 2 and 5 years. WT has overall survival rates exceeding 90% by the improvement of surgical and anesthetic procedures, and the combination of chemotherapy and radiotherapy (D’Angio et al. 1989; Argani and Beck­with 2004).
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Antibody targeting of tumor-associated vasculature is a promising therapeutic approach in human cancer; however, a specific cell membrane marker for endothelial cells of tumor vasculature has not been discovered yet. Endoglin (CD105) is a cell-surface glycoprotein most recently identified as an optimal indicator of proliferation of human endothelial cells. The finding that CD105 is over-expressed on vascular endothelium in angiogenetic tissues has prompted several pre-clinical studies designed to get a deeper understanding on the role of CD105 in angiogenesis, and to evaluate the most appropriate clinical setting(s) to utilize CD105 as a therapeutic target. In this review, the foreseeable clinical applications of CD105 in human cancer are discussed.
    Journal of Translational Medicine 07/2004; 2(1):18. DOI:10.1186/1479-5876-2-18 · 3.99 Impact Factor